Skip to main content
. 2014 Jul 29;16(4):R160. doi: 10.1186/ar4675

Figure 5.

Figure 5

Antiadalimumab antidrug antibodies can be masked by the presence of adalimumab in serum. Trough serum adalimumab levels (A) and antiadalimumab antidrug antibody (ADAb) titres (B) at the end of treatment (2 weeks after the last injection) and at follow-up (upon relapse or, in absence of relapse, at 16 weeks after discontinuation). *P < 0.05 assessed by Wilcoxon signed-rank test.